UNSPSC 51414102: Etofylline nicotinate

This classification denotes a vasodilating agent with the molecular formula C15H15N5O4, chemically known as 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl pyridine-3-carboxylate but generally known as Etofylline nicotinate, which bears US NIH Compound Identifier 83435. European Medicines Agency schedules Etofylline nicotinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07324MIG. World Health Organization schedules regadenoson in its Anatomical Therapeutic Chemical (ATC) Classification.

Most nations schedule etofylline nicotinate under HS 29395900 and SITC 54145. As of Q4 2014, ETOFYLLINE NICOTINATE remains the US FDA Preferred Term for this commodity. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCOC(=O)C3=CN=CC=C3.

UNSPSC 51414102 Etofylline nicotinate is a Commodity code covering pharmaceutical active ingredients and finished medications for emergency and clinical use by state and local health agencies. State and local governments procure specific medications under this code for emergency medical services, hospital systems, and health benefit programs. The issuing bodies include city fire rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances serving participating government facilities. Work solicited ranges from individual emergency medications for first-responder use to broad-based generic pharmaceutical supply agreements serving multiple jurisdictions and health care settings.

Recent activity spans Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications, including epinephrine, labetalol, adenosine, and diltiazem vials totaling approximately $40,000 for Tampa Fire Rescue, with a response deadline of April 8, 2026 and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with contract performance beginning July 1, 2026 and ongoing optional extensions through June 30, 2028. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in early April 2026 as preliminary market research for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement intent but no current contract award opportunity.